

Erik L. Grove

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3097290/publications.pdf>

Version: 2024-02-01

207
papers

7,710
citations

76326

40
h-index

58581

82
g-index

218
all docs

218
docs citations

218
times ranked

9765
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation. <i>European Heart Journal</i> , 2022, 43, e38-e44.	2.2	22
2	MicroRNA as Biomarkers for Platelet Function and Maturity in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 181-195.	3.4	13
3	Prognostic value of myocardial perfusion imaging after first-line coronary computed tomography angiography: A multi-center cohort study. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 34-40.	1.3	3
4	Association of whole blood microRNA expression with platelet function and turnover in patients with coronary artery disease. <i>Thrombosis Research</i> , 2022, 211, 98-105.	1.7	7
5	Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12629.	2.3	1
6	Warfarin monitoring and interference by lupus anticoagulant in patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2022, 211, 127-132.	1.7	1
7	Oral anti-coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. <i>British Journal of Haematology</i> , 2022, 197, 223-231.	2.5	6
8	Flow Cytometric Assessment of Changes in Platelet Reactivity after Acute Coronary Syndrome: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, .	2.7	2
9	Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 2022, 198, 693-702.	2.5	3
10	Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study. <i>International Journal of Cardiology</i> , 2022, 365, 34-40.	1.7	3
11	Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1182-1189.	1.2	12
12	All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f93-f100.	3.0	16
13	Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 520-529.	4.4	19
14	Micro- and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients: An exploratory study. <i>Clinical Transplantation</i> , 2021, 35, e14133.	1.6	6
15	Real-world experience with reversal of dabigatran by idarucizumab. <i>Thrombosis Research</i> , 2021, 197, 179-184.	1.7	11
16	Immature Platelets and Risk of Cardiovascular Events among Patients with Ischemic Heart Disease: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2021, 121, 659-675.	3.4	16
17	Platelet Function and Turnover in Essential Thrombocythemia: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 090-101.	2.7	10
18	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. <i>European Heart Journal</i> , 2021, 42, 2265-2269.	2.2	81

#	ARTICLE	IF	CITATIONS
19	Computed Tomographyâ€‘Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Real-World Cohort Study. <i>Journal of Computer Assisted Tomography</i> , 2021, 45, 408-414.	0.9	1
20	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. <i>Cancer Medicine</i> , 2021, 10, 4405-4414.	2.8	8
21	Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 800-814.	2.7	12
22	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998â€‘2018. <i>Scientific Reports</i> , 2021, 11, 13603.	3.3	8
23	A 19-Year-Old Man with a History of Recreational Inhalation of Nitrous Oxide with Severe Peripheral Neuropathy and Central Pulmonary Embolism. <i>American Journal of Case Reports</i> , 2021, 22, e931936.	0.8	9
24	Impact of Dose Reduction Strategies on Image Quality of Coronary CTA in Real-World Clinical Practice: A Subanalysis of PROTECTION VI Registry Data. <i>American Journal of Roentgenology</i> , 2021, 217, 1344-1352.	2.2	5
25	Coronary Flow Velocity Reserve and Myocardial Deformation Predict Long-Term Outcomes in Heart Transplant Recipients. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 1294-1302.	2.8	9
26	Reduction of Myocardial Infarction and All-Cause Mortality Associated to Statins in Patients Without Obstructive CAD. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2400-2410.	5.3	19
27	Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease. <i>TH Open</i> , 2021, 05, e230-e238.	1.4	4
28	Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 774-786.	1.0	2
29	Statistical and machine learning methods for analysis of multiplex protein data from a novel proximity extension assay in patients with ST-elevation myocardial infarction. <i>Scientific Reports</i> , 2021, 11, 13787.	3.3	1
30	Effectiveness and safety of oral anticoagulation treatment beyond 1Â‘year after venous thromboembolism in patients at intermediate recurrence risk. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 210-220.	2.5	2
31	Coronary CT angiography derived FFR in patients with left main disease. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3299-3308.	1.5	4
32	Different perceptions of thorax anatomy and hand placement for chest compressions among healthcare professionals and laypersons: Implications for cardiopulmonary resuscitation. <i>Resuscitation Plus</i> , 2021, 7, 100138.	1.7	1
33	Impact of centrifugation time and pneumatic tube transport on plasma concentrations of direct oral anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2021, , .	1.3	0
34	Coronary Atherosclerosis and Aortic Valve Disease as Long-Term Sequelae of Radiation Therapy in Childhood. <i>Case Reports in Cardiology</i> , 2021, 2021, 1-2.	0.2	0
35	Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and metaâ€‘analysis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 21-31.	2.5	13
36	Application of Low Tube Potentials inÂ‘CCTA. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 425-434.	5.3	29

#	ARTICLE	IF	CITATIONS
37	Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia. <i>Platelets</i> , 2020, 31, 365-372.	2.3	21
38	Benefits and Harm of Treatment with P2Y12 Inhibitors beyond 12 Months in Patients with Coronary Artery Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 446-456.	2.7	2
39	Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 075-082.	3.4	17
40	Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100629.	1.1	8
41	Electrical cardioversion of atrial fibrillation and atrial flutter: manoeuvres and tips to increase its effectiveness” Authors”™Reply. <i>Europace</i> , 2020, 22, 1602-1602.	1.7	0
42	Cohort selection in register”based studies of direct oral anticoagulant users with atrial fibrillation: An inevitable trade”off between selection bias and misclassification. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 3-5.	2.5	9
43	Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 7, 373-379.	3.0	5
44	Comorbidity and risk of venous thromboembolism after hospitalization for first”time myocardial infarction: A population”based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1974-1985.	3.8	0
45	The ABO Locus is Associated with Increased Fibrin Network Formation in Patients with Stable Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1248-1256.	3.4	7
46	Complex antithrombotic combinations: how to find the perfect blend?. <i>Heart</i> , 2020, 106, 557-558.	2.9	3
47	Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 371-378.	0.6	13
48	Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. <i>Europace</i> , 2020, 22, 1149-1161.	1.7	58
49	Efficacy and Safety of Oral Anticoagulants in Patients with Systolic Heart Failure in Sinus Rhythm: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Cohort Studies. <i>TH Open</i> , 2020, 04, e383-e392.	1.4	3
50	Direct Oral Anticoagulants After Percutaneous Patent Foramen Ovale (PFO) Closure: A Call for Caution. <i>American Journal of Case Reports</i> , 2020, 21, e922467.	0.8	3
51	Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit”A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 478-489.	2.7	22
52	Differential vascular effects of aspirin in people with Type 2 diabetes without cardiovascular disease and matched controls without diabetes. <i>Diabetic Medicine</i> , 2019, 36, 1141-1148.	2.3	2
53	The ABO locus is associated with increased platelet aggregation in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2019, 286, 152-158.	1.7	8
54	Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. <i>Heart</i> , 2019, 105, 742-748.	2.9	27

#	ARTICLE	IF	CITATIONS
55	A changing landscape: Temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006–2015. <i>Thrombosis Research</i> , 2019, 176, 46-53.	1.7	38
56	Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. <i>Scientific Reports</i> , 2019, 9, 20048.	3.3	2
57	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019, 286, 226-233.	1.7	28
58	Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. <i>Platelets</i> , 2019, 30, 322-328.	2.3	14
59	Apixaban or rivaroxaban in the treatment of acute venous thromboembolism?. <i>Annals of Translational Medicine</i> , 2019, 7, S206-S206.	1.7	2
60	P4792 Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
61	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	2.2	106
62	Use of Non-Vitamin K Antagonist Oral Anticoagulants 2008–2016: A Danish Nationwide Cohort Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 452-463.	2.5	45
63	Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 158-165.	3.0	6
64	Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 405-414.	1.2	45
65	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
66	von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 249-260.	2.7	35
67	Antiplatelet effect of aspirin during 24 h in patients with type 2 diabetes without cardiovascular disease. <i>Thrombosis Research</i> , 2018, 161, 1-6.	1.7	11
68	Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 174-181.	1.9	19
69	P2894 Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation: a propensity-weighted cohort study. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
70	Cardiovascular events after discontinuation of low-dose aspirin. <i>Journal of Thoracic Disease</i> , 2018, 10, 75-78.	1.4	1
71	Large Solid Right Atrial Thrombus Treated by AngioVac Catheter-Based Suction Thrombectomy. <i>Case Reports in Cardiology</i> , 2018, 2018, 1-3.	0.2	1
72	P4237 Gastrointestinal bleeding is associated with gastrointestinal cancer in patients with atrial fibrillation treated with anticoagulants - a nationwide study. <i>European Heart Journal</i> , 2018, 39, .	2.2	0

#	ARTICLE	IF	CITATIONS
73	P804The ABO gene locus is associated with increased platelet aggregation in stable coronary artery disease patients. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
74	3288CT-derived fractional flow reserve in patients with stable angina pectoris: A real world follow-up study. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
75	Neutrophil gelatinase-associated lipocalin (NGAL) and cardiovascular events in patients with stable coronary artery disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 470-476.	1.2	13
76	Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). <i>Stroke</i> , 2018, 49, 2568-2576.	2.0	50
77	Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction. <i>Thrombosis Research</i> , 2018, 172, 21-28.	1.7	17
78	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. <i>Scientific Reports</i> , 2018, 8, 15805.	3.3	14
79	P3189Aspirin for prevention of cardiovascular events: an analysis of 27,451 patients from the Western Denmark Cardiac Computed Tomography Registry. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
80	Effect of remote ischaemic conditioning on platelet aggregation and platelet turnover. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 528-533.	2.1	4
81	Platelet characteristics in patients with essential thrombocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 918-927.	1.5	33
82	Coronary CT Angiographic and Flow Reserve-Guided Management of Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2123-2134.	2.8	138
83	Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angiOgraphy iN daily practice in 2017 (PROTECTION VI). <i>European Heart Journal</i> , 2018, 39, 3715-3723.	2.2	149
84	Fibrin clot lysis assay: Establishment of a reference interval. <i>Thrombosis Research</i> , 2018, 167, 9-11.	1.7	16
85	Rationale and design of the worldwide prospective multicenter registry on radiation dose estimates of cardiac CT angiography in daily practice in 2017 (PROTECTION VI). <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 81-85.	1.3	12
86	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	2.2	86
87	Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. <i>Europace</i> , 2017, 19, euw241.	1.7	29
88	Clinical Use of Coronary CTAâ€œDerived FFRâ€œfor Decision-Making in Stable CAD. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 541-550.	5.3	126
89	Switching, Adverse Effects and Use of Overâ€œtheâ€œCounter Analgesics among Users of Oral Anticoagulants: A Pharmacyâ€œbased Survey. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 37-43.	2.5	10
90	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 221-234.	3.0	43

#	ARTICLE	IF	CITATIONS
91	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 875-883.	1.8	10
92	Thrombopoietin and platelet aggregation in patients with stable coronary artery disease. <i>Platelets</i> , 2017, 28, 822-824.	2.3	1
93	A genetic risk score predicts cardiovascular events in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2017, 241, 411-416.	1.7	16
94	Topical Antimycotics for Oral Candidiasis in Warfarin Users. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 368-372.	2.5	17
95	Effect of long-term remote ischaemic conditioning on platelet function and fibrinolysis in patients with chronic ischaemic heart failure. <i>Thrombosis Research</i> , 2017, 153, 40-46.	1.7	21
96	Myocardial Perfusion Imaging Versus Computed Tomography Angiographyâ€“Derived Fractional Flow Reserve Testing in Stable Patients With Intermediateâ€“Range Coronary Lesions: Influence on Downstream Diagnostic Workflows and Invasive Angiography Findings. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	23
97	The SH2B3 and KCNK5 loci may be implicated in regulation of platelet count, volume, and maturity. <i>Thrombosis Research</i> , 2017, 158, 86-92.	1.7	3
98	Platelet Function Tests: Preanalytical Variables, Clinical Utility, Advantages, and Disadvantages. <i>Methods in Molecular Biology</i> , 2017, 1646, 305-320.	0.9	27
99	Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14
100	Treatment Changes among Users of Nonâ€“Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 187-194.	2.5	35
101	Large atrial mass in a patient with Crohnâ€™s disease: organised thrombus mimicking a myxoma. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-222044.	0.5	0
102	Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. <i>American Journal of Case Reports</i> , 2017, 18, 945-948.	0.8	9
103	Late Obstructive Transcatheter Heart Valve Thrombosis Resolved by Rivaroxaban. <i>American Journal of Case Reports</i> , 2017, 18, 573-575.	0.8	5
104	Coronary artery disease-associated genetic variants and biomarkers of inflammation. <i>PLoS ONE</i> , 2017, 12, e0180365.	2.5	25
105	Inconsistencies in reporting of renal elimination among NOACs: the case of apixaban. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 346-348.	1.9	5
106	Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 336-343.	1.9	16
107	Preadmission use of selective serotonin reuptake inhibitors and shortâ€“term mortality in diabetic patients hospitalized due to stroke. <i>Journal of Internal Medicine</i> , 2016, 280, 407-418.	6.0	4
108	Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. <i>Heart</i> , 2016, 102, 1883-1889.	2.9	45

#	ARTICLE	IF	CITATIONS
109	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1494-1499.	1.3	11
110	Fatal stroke following treatment with apixaban in a patient with atrial fibrillation and left atrial appendage thrombus. <i>International Journal of Cardiology</i> , 2016, 214, 131-132.	1.7	6
111	Transcatheter Aortic Valve Thrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2059-2069.	2.8	312
112	The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics. <i>Advances in Experimental Medicine and Biology</i> , 2016, 906, 351-361.	1.6	8
113	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2016, 906, 325-350.	1.6	7
114	Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. <i>Thrombosis Research</i> , 2016, 148, 107-110.	1.7	13
115	Effect of remote ischaemic conditioning on coagulation and fibrinolysis. <i>Thrombosis Research</i> , 2016, 141, 129-135.	1.7	13
116	Limited public ability to recognise and understand the universal sign for automated external defibrillators. <i>Heart</i> , 2016, 102, 770-774.	2.9	13
117	Self-managed oral anticoagulant therapy: a call for implementation. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 255-257.	1.5	9
118	Platelets and Antiplatelet Therapy in Patients with Coronary Artery Disease and Diabetes. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 234-241.	2.7	25
119	The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	1.6	0
120	The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2015, 114, 519-529.	3.4	28
121	Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. <i>Thrombosis and Haemostasis</i> , 2015, 114, 459-468.	3.4	50
122	TALOS: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of Citalopram in Patients with Acute Stroke. <i>International Journal of Stroke</i> , 2015, 10, 985-987.	5.9	34
123	Coronary stents and non-cardiac surgery: to bridge or not to bridge?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 211-213.	3.4	0
124	The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. <i>PLoS ONE</i> , 2015, 10, e0132629.	2.5	15
125	Autoresuscitation: A Case and Discussion of the Lazarus Phenomenon. <i>Case Reports in Medicine</i> , 2015, 1-5.	0.7	11
126	Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. <i>Platelets</i> , 2015, 26, 230-235.	2.3	31

#	ARTICLE	IF	CITATIONS
127	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 2015, 170, 465-470.	2.7	11
128	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 2133-2147.	1.8	30
129	Life-Threatening Contraceptive-Related Pulmonary Embolism in a 14-Year-Old Girl with Hereditary Thrombophilia. American Journal of Case Reports, 2015, 16, 667-669.	0.8	4
130	Calprotectin and Platelet Aggregation in Patients with Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0125992.	2.5	17
131	Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0126767.	2.5	37
132	Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Advances in Experimental Medicine and Biology, 2015, , .	1.6	0
133	Platelet Turnover in Stable Coronary Artery Disease â€“ Influence of Thrombopoietin and Low-Grade Inflammation. PLoS ONE, 2014, 9, e85566.	2.5	50
134	The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thrombosis and Haemostasis, 2014, 112, 1142-1150.	3.4	49
135	Left atrial papillary fibroelastoma as an unusual cause of myocardial infarction. BMJ Case Reports, 2014, 2014, bcr2014206665-bcr2014206665.	0.5	3
136	Huge right atrial thrombus after discontinuation of anticoagulant therapy in atrial fibrillation. BMJ Case Reports, 2014, 2014, bcr2014204999-bcr2014204999.	0.5	0
137	Response: Is heart failure a debatable endâ€­point for bisphosphonate treatment in an older osteoporotic population?. Journal of Internal Medicine, 2014, 275, 198-198.	6.0	0
138	Successful implementation of the European Resuscitation Council basic life support course as mandatory peer-led training for medical students. European Journal of Emergency Medicine, 2014, 21, 142-144.	1.1	3
139	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. PLoS ONE, 2014, 9, e113627.	2.5	22
140	Rapid evaluation of platelet function using the MultiplateÂ® Analyzer. Platelets, 2014, 25, 628-633.	2.3	43
141	New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta Anaesthesiologica Scandinavica, 2014, 58, 651-659.	1.6	25
142	Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporosis International, 2014, 25, 757-762.	3.1	64
143	A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thrombosis Research, 2014, 134, 1253-1264.	1.7	48
144	Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. Thrombosis Research, 2014, 133, 1161-1163.	1.7	5

#	ARTICLE	IF	CITATIONS
145	24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. <i>International Journal of Cardiology</i> , 2014, 175, 274-279.	1.7	43
146	Can we improve the efficacy of low-dose aspirin?. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1077-1078.	3.4	10
147	Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1. <i>PLoS ONE</i> , 2014, 9, e111816.	2.5	39
148	Gastrointestinal Events with Clopidogrel: A Nationwide Population-Based Cohort Study. <i>Journal of General Internal Medicine</i> , 2013, 28, 216-222.	2.6	27
149	Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. <i>European Heart Journal</i> , 2013, 34, 1708-1713.	2.2	159
150	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1627-1639.	3.8	28
151	Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. <i>Platelets</i> , 2013, 24, 528-537.	2.3	27
152	Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2013, 109, 920-929.	3.4	27
153	Letter by Grove and Kristensen Regarding Article, "Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With ST-segment Elevation Myocardial Infarction in Circulation: Cardiovascular Interventions, 2013, 6, e28.	3.9	0
154	Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 642-650.	3.8	3
155	Heart failure in patients treated with bisphosphonates. <i>Journal of Internal Medicine</i> , 2013, 274, 342-350.	6.0	20
156	Platelet function testing and prediction of procedural bleeding risk. <i>Thrombosis and Haemostasis</i> , 2013, 109, 817-824.	3.4	30
157	Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. <i>PLoS ONE</i> , 2013, 8, e71150.	2.5	32
158	Timing of Acute Myocardial Infarction in Patients Undergoing Total Hip or Knee Replacement. <i>Archives of Internal Medicine</i> , 2012, 172, 1229.	3.8	67
159	Pharmacogenetics of the Antiplatelet Effect of Aspirin. <i>Current Pharmaceutical Design</i> , 2012, 18, 5294-5308.	1.9	37
160	Editorial: Paving the Way for Improved Antiplatelet Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 5195-5196.	1.9	0
161	Platelet Function Testing in Atherothrombotic Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5379-5391.	1.9	35
162	Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance. <i>Current Pharmaceutical Design</i> , 2012, 18, 5344-5361.	1.9	59

#	ARTICLE	IF	CITATIONS
163	Contemporary use of glycoprotein IIb/IIIa inhibitors. <i>Thrombosis and Haemostasis</i> , 2012, 107, 215-224.	3.4	54
164	Charging the defibrillator before rhythm check reduces hands-off time during CPR: A randomised simulation study. <i>Resuscitation</i> , 2012, 83, e210-e211.	3.0	5
165	Combining aspirin and proton pump inhibitors: for whom the warning bell tolls?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1051-1055.	3.3	10
166	Reply to Letter: Basic Life Support-becoming more complex. <i>Resuscitation</i> , 2012, 83, e25-e26.	3.0	0
167	Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. <i>Thrombosis Research</i> , 2012, 129, 434-440.	1.7	20
168	Platelet aggregation is dependent on platelet count in patients with coronary artery disease. <i>Thrombosis Research</i> , 2012, 129, 56-61.	1.7	100
169	Direct mail improves knowledge of basic life support guidelines in general practice: a randomised study. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2012, 20, 72.	2.6	7
170	The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. <i>Nature Reviews Cardiology</i> , 2012, 9, 658-670.	13.7	121
171	New Oral Anticoagulants. <i>Drugs</i> , 2012, 72, 1739-1753.	10.9	76
172	Shear-induced platelet aggregation in aspirin-treated patients: Initial experience with the novel PlaCor PRTA® device. <i>Thrombosis Research</i> , 2012, 130, 753-758.	1.7	10
173	Initial assessment and treatment with the Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach. <i>International Journal of General Medicine</i> , 2012, 5, 117.	1.8	176
174	Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2012, 108, 140-147.	3.4	17
175	P2Y12 inhibitors in acute coronary syndromes: How do we choose the best drug for our patients?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 203-205.	3.4	3
176	Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. <i>Journal of Internal Medicine</i> , 2012, 272, 385-393.	6.0	30
177	Antiplatelet Therapy in Patients with Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2012, 10, 494-505.	1.7	27
178	Increased Inflammatory Markers in Patients with Reduced Antiplatelet Effect of Aspirin.. <i>Blood</i> , 2012, 120, 2252-2252.	1.4	0
179	Antiplatelet effect of aspirin in patients with coronary artery disease. <i>Danish Medical Journal</i> , 2012, 59, B4506.	0.5	13
180	Visual-aided directions are superior to verbal instruction only in obtaining hand position for cardiopulmonary resuscitation. <i>American Journal of Emergency Medicine</i> , 2011, 29, 1178-1181.	1.6	2

#	ARTICLE	IF	CITATIONS
181	Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. <i>Thrombosis and Haemostasis</i> , 2011, 106, 182-184.	3.4	14
182	Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 185-191.	3.8	123
183	Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 889-890.	3.8	2
184	Increased platelet turnover in patients with previous definite stent thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1418-1419.	3.8	23
185	Benefits and shortcomings of mandatory first aid and basic life support courses for learner drivers. <i>Resuscitation</i> , 2011, 82, 614-617.	3.0	14
186	Mouth-to-mouth ventilation is superior to mouth-to-pocket mask and bag-valve-mask ventilation during lifeguard CPR: A randomized study. <i>Resuscitation</i> , 2011, 82, 618-622.	3.0	47
187	Intraosseous Catheter Placement in Children. <i>New England Journal of Medicine</i> , 2011, 364, 2171-2171.	27.0	2
188	Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. <i>BMJ: British Medical Journal</i> , 2011, 342, d2690-d2690.	2.3	161
189	Cardiac Arrest Caused by Multiple Recurrent Pulmonary Embolism. <i>Case Reports in Medicine</i> , 2011, 2011, 1-4.	0.7	1
190	Patients With Previous Definite Stent Thrombosis Have a Reduced Antiplatelet Effect of Aspirin and a Larger Fraction of Immature Platelets. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 828-835.	2.9	62
191	A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1245-1253.	3.4	125
192	The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. <i>Heart</i> , 2010, 96, 368-371.	2.9	111
193	Aspirin and coronary artery disease. <i>Heart</i> , 2010, 96, 1684-1684.	2.9	0
194	Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. <i>Thrombosis Research</i> , 2010, 126, e318-e322.	1.7	61
195	Evaluation of aspirin response by Multiplate® whole blood aggregometry and light transmission aggregometry. <i>Platelets</i> , 2009, 20, 415-420.	2.3	38
196	Update on oral antiplatelet therapy: principles, problems and promises. <i>Future Cardiology</i> , 2009, 5, 247-258.	1.2	29
197	International Sign for Automated External Defibrillator. <i>Annals of Emergency Medicine</i> , 2009, 54, 855-856.	0.6	3
198	Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. <i>Thrombosis Research</i> , 2009, 124, 96-100.	1.7	36

#	ARTICLE	IF	CITATIONS
199	The right oral antithrombotics in acute coronary syndromes. <i>Lancet</i> , The, 2009, 374, 1947-1948.	13.7	11
200	Immature platelets in patients with acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2009, 101, 151-153.	3.4	171
201	Immature platelets in patients with acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2009, 101, 151-6.	3.4	43
202	Aspirin response evaluated by the VerifyNow [®] , [†] Aspirin System and Light Transmission Aggregometry. <i>Thrombosis Research</i> , 2008, 123, 267-273.	1.7	78
203	Monitoring aspirin therapy with the Platelet Function Analyzer [®] 100. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 786-792.	1.2	8
204	Aspirin resistance: myth or major problem?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 257-259.	1.2	6
205	Platelet function testing in atherothrombotic disease: steps forward in managing resistance to antiplatelet therapy. <i>Kardiologia Polska</i> , 2008, 66, 478-9.	0.6	0
206	The platelet polymorphism PIA2 is a genetic risk factor for myocardial infarction. <i>Journal of Internal Medicine</i> , 2004, 255, 637-644.	6.0	43
207	Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts. <i>Scandinavian Cardiovascular Journal</i> , 2003, 37, 205-210.	1.2	4